Saturday 17 October 2026 Export CRIS’s income statement to Excel — free account

Curis, Inc.

Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024. In the quarter to June 2026, revenue fell 66.0%, EPS grew 70.4% and free cash flow fell 20.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.41 0.10 −19.61%

Follow CRIS

Alert me

Market cap: $1.1M
P/E: 0.0×
Fwd P/E: −0.3×
Dividend yield: —
F-score: 4/9
Altman Z: −87.83
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 19.00%

Capital & Financial Ratios $m

Market Cap 1.06

Revenue 9.44

Net Income (21.15)

Free Cash Flow (30.59)

Net Debt (5.62)

Current Ratio 0.49

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.30)

P/S ratio 0.09

P/B ratio 0.19

Past 5Y EPS Growth —

This Y EPS Growth (306.38%)

Next Y EPS Growth 87.24%

Next Y revenue growth (2.04%)

Next 5Y EPS Growth 15.90%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.04%

10-year low 10-year high

P/B against its own 10 years 0.05%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	56	20	5	6
Receivables	3	3	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	61	26	7	7

	2023	2024	2025	Q'26
Payables	3	3	6	5
ST’ Debt	—	—	—	—
Other	9	8	—	—
	22	19	14	14

Compound Annual Growth %

	10y	5y	3y
Sales	1.83%	(2.71%)	(2.42%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(21.88%)	(47.00%)	(51.04%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	2	3	3	1	9
’24	2	3	3	3	11
’23	2	2	3	3	10
’22	2	2	3	3	10
’21	2	2	3	3	11
’20	3	2	3	3	11

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(10)	—	—	—
’25	(7)	(8)	(6)	(6)	(27)
’24	(13)	(11)	(6)	(9)	(40)
’23	(12)	(8)	(8)	(10)	(38)
’22	(17)	(12)	(13)	(12)	(54)
’21	(13)	(7)	(10)	(8)	(38)
’20	(9)	(5)	(6)	(6)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(10)	—	—	—
’25	(7)	(8)	(6)	(6)	(27)
’24	(13)	(11)	(6)	(9)	(40)
’23	(12)	(8)	(8)	(10)	(38)
’22	(17)	(12)	(13)	(12)	(55)
’21	(13)	(7)	(10)	(8)	(38)
’20	(9)	(5)	(6)	(6)	(26)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(25.00)	(4.02)	—	—	—
’25	(25.00)	(13.60)	(9.80)	24.60	(11.60)
’24	(41.00)	(40.60)	(34.00)	(25.00)	(137.60)
’23	(48.00)	(48.00)	(42.60)	(40.60)	(179.20)
’22	(72.00)	(68.00)	(56.00)	(48.00)	(244.00)
’21	(44.00)	(48.00)	(48.00)	(60.00)	(200.00)
’20	(112.00)	(68.00)	(44.00)	(44.00)	(244.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2,500.00	1,380.00	240.00	272.00	248.00	1,724.00	188.00	76.00	57.20	19.20	Analyst estimates 2026–2028 Powerpack
	High	7,440.00	6,760.00	2,080.00	1,160.00	3,680.00	6,960.00	2,108.00	400.00	349.80	90.00
People
People	Employees	58	55	31	28	28	41	51	49	34	24
	Revenue/emp, $m	0.13	0.18	0.34	0.36	0.39	0.26	0.20	0.20	0.32	0.39
Income, $m
Income, $m	Revenue	8	10	10	10	11	11	10	10	11	9
	Gross margin, %	94.70	94.99	94.60	94.97	95.07	94.99	97.47	97.88	99.10	99.52
	EBT	(60)	(53)	(33)	(32)	(30)	(45)	(57)	(47)	(43)	(8)
	EBT margin, %	(802.59)	(538.66)	(312.38)	(321.28)	(276.03)	(426.67)	(557.69)	(473.04)	(397.77)	(80.29)
	Net income	(60)	(53)	(33)	(32)	(30)	(45)	(57)	(47)	(43)	(8)
	Depreciation	0	0	0	0	0	2	1	(1)	0	0
Per share, $
Per share, $	Revenue	113.36	132.68	125.94	120.53	89.03	46.52	43.52	37.87	34.60	14.35
	Earnings	(900.00)	(720.00)	(392.00)	(388.00)	(244.00)	(200.00)	(244.00)	(179.20)	(137.60)	(11.60)
	Cash flow	(539.32)	(648.19)	(363.10)	(315.72)	(211.50)	(164.35)	(232.71)	(145.20)	(125.48)	(41.33)
	Capex	(4.95)	(2.52)	(1.03)	(0.49)	(5.56)	0.00	(1.78)	0.00	0.00	0.00
	Free cash flow	(544.28)	(650.71)	(364.13)	(316.22)	(217.06)	(164.35)	(234.49)	(145.20)	(125.48)	(41.33)
	Book value	440.75	321.62	(54.30)	(408.57)	1,073.71	396.27	199.37	74.31	(19.02)	8.30
	Shares, m	0	0	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	57.16	11.15	2.19	5.64	36.80	40.93	5.70	6.58	1.77	1.38
	P/B	14.70	4.60	0.00	0.00	3.05	4.80	1.24	3.35	0.00	2.39
	EV/Sales	53.89	9.27	3.27	9.83	21.33	30.16	(2.61)	1.08	0.05	0.97
	EV/FCF	(11.22)	(1.89)	(1.13)	(3.75)	(8.75)	(8.39)	0.48	(0.28)	(0.01)	(0.33)
Cash, $m
Cash, $m	Operating cash flow	(36)	(48)	(30)	(26)	(26)	(38)	(54)	(38)	(40)	(27)
	Capex	0	0	0	0	(1)	—	0	—	—	—
	Free cash flow	(36)	(49)	(30)	(26)	(26)	(38)	(55)	(38)	(40)	(27)
Balance, $m
Balance, $m	Working capital	35	50	15	18	163	109	82	39	7	(7)
	Total debt	20	42	35	63	1	59	53	—	—	—
	Net debt	(25)	(19)	11	42	(168)	(116)	(86)	(56)	(20)	(5)
	Shareholders’ equity	29	24	(4)	(34)	131	91	47	20	(6)	5
Returns, %
Returns, %	ROA	(79.11)	(81.06)	(58.61)	(88.70)	(24.98)	(24.78)	(41.80)	(50.95)	(73.20)	(24.77)
	ROIC	(781.61)	(585.03)	(272.90)	(189.43)	0.00	0.00	0.00	0.00	0.00	(890.43)
	ROE	(128.84)	(200.22)	(334.15)	167.37	(61.82)	(41.05)	(82.58)	(143.19)	(634.72)	2,829.10

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PTIX Atrinsic Inc.	$1.3M	0.3×	—	+34.31% (above 0%: growing)	n/m	+46.07% (above 0%: growing)	0.00%	0.00%	Compare
SPRC SciSparc Ltd.	$1.2M	— (loss-making)	7.9×	—	n/m	+14.95% (above 0%: growing)	35.75%	0.00%	Compare
CYTOF Altamira Therapeutics Ltd.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+85.35% (above 0%: growing)	(157.79%)	0.00%	Compare
BBLG Bone Biologics Corp.	$1.1M	— (loss-making)	—	—	n/m	−12.97% (below 0%: shrinking)	—	0.00%	Compare
BPTH Bio-Path Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+98.68% (above 0%: growing)	0.00%	0.00%	Compare
CRIS Curis, Inc.	$1.1M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%
MNTRQ 9 Meters Biopharma, Inc.	$1.0M	— (loss-making)	—	−25.99% (below 0%: shrinking)	n/m	+0.01% (above 0%: growing)	0.00%	0.00%	Compare
ZVSA ZyVersa Therapeutics, Inc.	$970.0K	— (loss-making)	—	—	n/m	+54.91% (above 0%: growing)	0.00%	0.00%	Compare
LYRA Lyra Therapeutics, Inc.	$870.0K	— (loss-making)	— (loss-making)	−96.65% (below 0%: shrinking)	n/m	+45.44% (above 0%: growing)	100.00%	(101,685.71%)	Compare
Median of peers	$1.1M	—	—	−25.99%	—	+45.76%	0.00%	0.00%

All 614 Biotechnology stocks →

Curis, Inc. (CRIS) key facts

Concern: Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024.
Curis, Inc. (CRIS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CRIS traded at $0.41, a market capitalization of $1.1 million.
Return on equity was 2,829.1% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −87.83 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.